FDA Warning: Peanuts Detected in Certain Ritz Cracker Sandwiches Prompting Recall

The FDA has issued a risk warning and recall for certain Ritz cracker sandwiches due to undeclared peanuts, posing a serious allergy risk. Consumers should check labels carefully.
The U.S. Food and Drug Administration (FDA) has issued a risk warning concerning specific Ritz cracker sandwich products due to the potential presence of undeclared peanuts, a major allergen. This alert follows a voluntary recall announced by Mondelēz Global LLC on July 8, 2025. The recall affects several product sizes, including the Ritz Peanut Butter Cracker Sandwiches in 8-pack, 20-pack, and 224-case quantities, as well as the Ritz Filled Cracker Sandwich 20-count variety pack.
The recall was initiated after the discovery that packaging films used for wrapping individual peanut butter products may contain defects caused by a supplier error. While the outer cartons were correctly labeled to indicate the presence of peanuts, some individual packs were mislabeled as cheese sandwiches. Consumers with peanut allergies are strongly advised not to consume these products, which could cause serious or life-threatening allergic reactions such as hives, lip swelling, or anaphylaxis.
To date, no injuries or illnesses have been reported. The affected products have specific UPC codes and best-by dates ranging from November 2025 to January 2026. These products were sold nationwide at retail stores.
The allergen labeling error posed a serious health risk to individuals allergic to peanuts, making it crucial for consumers to check product labels carefully. Mondelēz Global LLC has assured that corrective actions are underway to prevent future issues.
For those who purchased these products and have peanut allergies, it is recommended to contact the company at 844-366-1171 for further assistance. Consumers are also encouraged to learn more about peanut allergies through reputable sources such as the American Academy of Allergy, Asthma & Immunology.
Source: https://medicalxpress.com/news/2025-07-ritz-fda-issues-due-undeclared.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Questioning the Reliability of FDA-Approved Metrics for Rectal Cancer Drug Effectiveness
A new study questions the reliability of the FDA-supported metric, pathologic complete response, used to evaluate the effectiveness of rectal cancer treatments, suggesting it may not predict long-term survival.
Microscopic Plant Particles Can Lead to Permanent Damage to Tooth Enamel
Emerging studies highlight how microscopic plant particles, or phytoliths, can cause irreversible damage to tooth enamel, emphasizing the importance of understanding food-related dental wear and maintaining oral health.
Small Walking Technique Adjustments May Aid in Managing Knee Osteoarthritis
Adjusting your walking posture slightly can reduce knee pain and slow osteoarthritis progression. A recent study highlights the benefits of personalized gait retraining as a non-invasive treatment option.



